TRANSITION AND SEPARATION AGREEMENTTransition and Separation Agreement • November 6th, 2017 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • California
This Transition and Separation Agreement (the “Agreement”) by and between Stephen G. Dilly, M.B.B.S., Ph.D. (“Executive”), and Aimmune Therapeutics, Inc., a Delaware corporation (the “Company”), is made effective as of the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts:
